New Drug Research

Drug Candidate Screening

NEXEL Co., Ltd. is developing safe and efficient drug development candidates derived from bioactive proteins secreted by hiPSC-derived functional cells.

NEXEL Pipeline

<Last update: Dec. 10, 2020>

Drug Candidate Screening

NEXEL’s pipeline and their target indications

  • 01
    Liver fibrosis
    Inhibits liver fibrosis by inactivating hepatic stellate cells
  • 02
    Myocardial Infarction
    Reduction of the area of damage in myocardium and recovery of cardiac function
  • 03
    Alcoholic Hepatitis
    Biomarker for diagnosis and prediction of severe alcoholic hepatitis patients

    Prevention of alcoholic liver damage & Induction of tisue regeneration
  • 04
    Idiopathic Pulmonary Fibrosis
    Inhibits lung fibrosis by inhibiting fibroblast to myofibroblast transition (FMT), the main cause of pulmonary fibrosis
  • Drug Candidate Screening
    Liver fibrosis
    Alcoholic Hepatitis
  • Drug Candidate Screening
    Myocardial
    Infarction
  • Drug Candidate Screening
    Lung Fibrosis

NP-011 is NEXEL’s human recombinant protein, pre-clinical stage candidate proven by drug candidate screening with exceptional anti-fibrotic activity and safety.

NEXEL is continually seeking partners to bring the candidate successfully to commercialization through drug candidate screening.

  • logoCONTACT

    Contact Information

    • Address: 8F, 55 Magokdong-ro, Gangseo-gu, Seoul, Republic of Korea(07802)

    • Business Registration No.: 109-86-37282
    • CEO: Choongseong Han

    • Tel: +82-2-2088-8886
    • Fax: +82-2-2088-8884
    • E-mail: support@nexel.co.kr